In one paragraphArticle in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
8 authors.
Hannah Painter *Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0003-0445-7473 Sasha E Larsen *Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.ORCID 0000-0001-5034-9727 Brittany D WilliamsCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Hazem F M AbdelaalCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Susan L BaldwinCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Helen A FletcherDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Andrew Fiore-GartlandBiostatistics, Bioinformatics and Epidemiology Program, Fred Hutch Cancer Center, Seattle, Washington, USA.ORCID 0000-0001-7627-2166 Rhea N ColerCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.ORCID 0000-0001-6974-5666 Funding
IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB)75N93021C00029 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI COLER, RHEA · 2022 to 2025
$35.2MImmunotherapy to prevent drug-resistant tuberculosisR01AI125160 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI BALDWIN, SUSAN LOUISE, COLER, RHEA N · 2016 to 2020
$6.6MDiseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3MSeattle Tuberculosis Research Advancement CenterP30AI168034 · NIAID · UNIVERSITY OF WASHINGTON · PI Thomas R Hawn · 2022 to 2026
$6.3MUnderstanding the Function of F13 as a Matrix Protein for Poxvirus Intracellular EnvelopmentR01AI168023 · NIAID · UNIVERSITY OF ROCHESTER · PI BRIAN M WARD · 2023 to 2026
$1.5MMRC and BBSRC MR/R005850/1National Institutes of Health T32 AI00750922NIAID NIH HHS 75N93021C00029NIAID NIH HHS P30 AI168034NIAID NIH HHS R01 AI125160NIAID NIH HHS R01 AI168023NIAID NIH HHS T32 AI007509UK Medical Research Council MR/N013638/1
6 · The paper itselfAbstract
It is unclear whether human progression to active tuberculosis disease (TB) risk signatures are viable endpoint criteria for evaluations of treatments in development. TB is the deadliest infectious disease globally and more efficacious vaccines are needed to reduce this mortality. However, the immune correlates of protection for either preventing infection with IMPORTANCE: Understanding the strengths or limitations of back-translating human-derived correlate of risk (COR) RNA signatures into the preclinical pipeline may help streamline down-selection of therapeutic vaccine and drug candidates and better align preclinical models with proposed clinical trial efficacy endpoints.
Indexed as
RNATuberculosisDisease ProgressionHumansMycobacterium tuberculosisTranscriptomeTuberculosis VaccinesRNATuberculosis Vaccinescorrelate of riskpreclinical drug studiesRNA risk signaturetuberculosistuberculosis vaccines
Identifiers
PMID39651886
PMCPMC11774039
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390